New hope for children with rare non-Hodgkin lymphoma

15 January 2021
pfizer_colour_new_large

New York-based Pfizer (NYSE: PFE) has broadened the US label for Xalkori (crizotinib), to include treatment of young adults and children over the age of 1 with anaplastic large cell lymphoma (ALCL).

The US Food and Drug Administration approval covers treatment for ALK-positive tumors, as defined by a genetic test, which have not responded well to initial treatment.

ALCL is a rare form of non-Hodgkin lymphoma which accounts for around a third of cases of NHL in young people, the vast majority of which are ALK-positive.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical